Anticoagulant-related bleeding carries considerable morbidity and mortality. Major or life-threatening bleeding is among the most severe of these complications. As the number of patients treated with direct oral anticoagulants (DOACs) continues to increase, so does the number of DOAC-related bleeding events. The incidence of CRNM bleeding related to DOAC therapy ranges from 15 to 18% per 100-year patients, while the incidence of major bleeding ranges from 2.71 to 3.6%. Many of these bleeding events can be prevented with tailored dosing regimens or proper peri-procedural management. When unable to be prevented, DOAC-related bleeding can lead to significant long-term disability or death. Management with newer reversal agents such as andexanet alfa and idarucizumab, as well as prothrombin complex concentrates, may improve outcomes for patients with DOAC-related bleeding. The purpose of this review is to explore strategies for preventing and treating bleeding in patients receiving DOACs for anticoagulant therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40265-020-01345-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of DOAC-related bleeding in cancer patients: a single center-case series.
J Thromb Thrombolysis
April 2024
The University of Texas MD Anderson Cancer Center, Section of Benign Hematology, 1515 Holcombe Blvd. Unit 1464, Houston, TX, 77030, USA.
Venous thromboembolism (VTE) and stroke carry significant mortality and morbidity in cancer patients. Direct oral anticoagulants (DOACs) have been demonstrated to be effective for the treatment of VTE and prevention of stroke in atrial fibrillation (AF). Bleeding rates are variable and are based on the cancer type and the patient's specific risk factors.
View Article and Find Full Text PDFAntidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma.
Curr Opin Anaesthesiol
April 2024
Department of Anaesthesiology, RWTH Aachen University Hospital, Aachen, Germany.
Article Synopsis
- - The introduction of direct oral anticoagulants (DOACs) has improved anticoagulant treatments, but they can also increase the risk of severe bleeding, complicating treatment, especially after injuries.
- - Recent studies highlight the importance of quickly reversing DOAC effects during major bleeding, showing that antidotes like andexanet alfa and idarucizumab, as well as prothrombin complex concentrates (PCCs), can effectively counteract these effects.
- - Current guidelines suggest using specific antidotes and PCCs for managing major bleeding related to DOACs, but more randomized trials are needed to better understand their effectiveness and safety in this context.
Risk scores for major bleeding from direct oral anticoagulants: comparing predictive performance in patients with atrial fibrillation.
Res Pract Thromb Haemost
January 2024
Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Background: Despite direct oral anticoagulants (DOACs) being safer than warfarin for stroke prevention in atrial fibrillation (AF), major bleeding concerns persist. Most bleeding risk scores predate DOAC approval.
Objectives: This study aimed to compare the Age, history of Bleeding, and non-bleeding related Hospitalisation [ABH] score's performance-derived for DOAC-treated patients-with those of 5 other scores (Anticoagulation and Risk Factors in Atrial Fibrillation [ATRIA], Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly [>65 years], Drugs/alcohol concomitantly [HAS-BLED], Hepatic, Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall Risk and Stroke [HEMORRHAGES], Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF], and Congestive heart failure, Hypertension, Age ≥75 [doubled], Diabetes, Stroke [doubled]-Vascular disease, Age 65-74, Sex category [CHADS-VASc]) in predicting DOAC-related major bleeding in patients with AF.
Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era.
Eur J Intern Med
May 2024
Division of Cardiology, Kohka Public Hospital, Koka, Japan.
Background: There have been still limited data on the transition of management strategies and clinical outcomes after introduction of direct oral anticoagulant (DOAC) for cancer-associated venous thromboembolism (VTE) in the real-world clinical practice.
Methods: Using the 2 series of multicenter COMMAND VTE registries in Japan enrolling consecutive patients with acute symptomatic VTE, we compared 695 patients with cancer-associated VTE in the Registry-1 of the warfarin era and 1507 patients in the Registry-2 of the DOAC era.
Results: Regarding oral anticoagulation therapy, 576 patients (82.
Epidemiology and outcomes of intracerebral hemorrhage associated with oral anticoagulation over 10 years in a population-based stroke registry.
Int J Stroke
June 2024
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Background: Recent years have seen a change in the use of anticoagulants in the general population due to the availability of direct oral anticoagulants (DOACs) as an alternative to vitamin K antagonists (VKAs) and increased detection of atrial fibrillation. It is important to have updated epidemiological data to understand how this change is impacting on the occurrence and outcome of intracerebral hemorrhage (ICH).
Patients And Methods: Our prospective population-based registry included patients with first-ever ICH occurring from January 2011 to December 2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!